Blogs
Can evidence of health inequality tilt the balance of a NICE assessment?
By Fisentzos Stylianou, PhD Contact: Fstylianou@partners4access.com In November 2021, Novartis’ Adakveo (crizanlizumab) became the first treatment for sickle cell disease (SCD) to be made available
February 14, 2022
